Ph 2 Clinical Trial initiated for CLDN18.2 CAR T-cell Product CT041 in the U.S.
Dr Raffaele Baffa, Chief Medical Officer of CARsgen, commented that, “Gastric cancer is a devastating disease that affects over a million people worldwide. Despite advances in treatment, the prognosis for patients with advanced gastric cancer remains poor, highlighting the urgent need for new and innovative therapies. CT041 has shown promising results in previous trials, demonstrating clinical efficacy and a manageable safety profile. We believe that CT041 has the potential to become an effective treatment option for patients with advanced gastric cancer. We would also like to express our gratitude to the patients, investigators, and our dedicated team at CARsgen for their commitment to advancing the field of cancer immunotherapy. We look forward to sharing updates on our clinical progress as we continue to work towards our goal of developing innovative CAR T-cell therapies for patients.”
Share:
More News
Dr. Hui Zhou, Chief R&D Officer (oncology pipeline) of Innovent Biologics, said, ” Patients with advanced gastric cancer generally have a poor prognosis after initial lines of treatment and are prone to rapid disease progression. There is a lack of effective subsequent treatment options, with median survival of only around
OriCell co-founder, Chairman and Chief Executive Officer Dr. Yang Huanfeng commented: “We are deeply grateful to the NMPA Centre for Drug Evaluation and relevant government authorities for their strong support of innovative drug development, and to Academician Fan, Professor Qin and their teams for their trust and active participation. This
Louise Modis, Chief Executive Officer at Amphista, said: “FDA clearance of our IND for AMX-883, our lead Targeted Glue™, for acute myeloid leukaemia is a significant milestone as we transition into a clinical-stage company. AMX-883 is the only BRD9 degrader currently being developed and the compelling preclinical findings submitted to
“Giredestrant represents the first major endocrine therapy advance in early-stage ER-positive breast cancer in decades, where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The FDA’s filing acceptance brings us closer to delivering a new standard-of-care with the